Replies to post #20576 on Synaptogenix Inc (SNPX)

[runncoach]

You know Theburg, you have a point. They could announce dosing complete but as you say, the trial isn't finished because of the the 40 week extension. Interesting thought.

[InTheTrenches]

Also, we have a new CEO. It is the discretion of the CEO (and COB) as to what to PR. Perhaps this CEO has a more conservative view on what needs to be put in a PR?

Having said that, I agree with most on this board, that it would be better to be consistent with past practices.

[Plummy Potter]

This make a lot of sense. In fact, the previous two PRs announced that the company had concluded "dosing and monitoring" (2017) and "data collection" (2019). They won't be able to make those claims in this case until the 42 week follow-up has been completed for all patients. Not sure when to expect that...

https://www.prnewswire.com/news-releases/neurotrope-bioscience-concludes-patient-dosing-and-monitoring-in-its-148-patient-phase-2-clinical-trial-of-moderate-to-severe-alzheimers-dementia-300414678.html

https://www.americanpharmaceuticalreview.com/1315-News/362700-Neurotrope-Concludes-Data-Collection-in-Alzheimer-s-Disease-Clinical-Trial/